Prognostic nutritional index (PNI), which is calculated using the albumin level reflecting nutritional status and lymphocyte count reflecting immune status, is useful in showing nutritional and immunological status related to survival and prognosis in many cancers. In this study, we aimed to evaluate the biomarker potential and effect of PNI in determining the prognosis of metastatic castration-sensitive prostate cancer (mCSPC). This retrospective observational study included the complete data of 108 patients with mCPSC who were treated for at least three months between 1 January 2010, and 1 June 2021. The relationships between cancer-specific survival (CSS), overall survival (OS), progression-free survival (PFS), and PNI were evaluated. The Kaplan–Meier method for OS, PFS, and CSS, as well as univariate and multivariate Cox regression models, were used for the statistical analyses. The median age of 108 patients included in the study was 68.54 (61.05–74.19) years. A value of 49.75 was determined to be the best cut-off point for the PNI. OS (months) was found to be significantly lower in patients with low PNI (median: 34.93, 95% CI: 21.52–48.34) than in patients with high PNI (median: 65.60, 95% CI: 39.36–91.83) (p = 0.016). Patients with high PNI (median: 48.20, 95% CI: 34.66–61.73) had significantly better CSS (months) than patients with low PNI (median: 27.86, 95% CI: 24.16–31.57) (p = 0.001). There was no statistically significant difference in PFS between patients with high PNI values (median: 24.60, 95% CI: 10.15–39.05) and patients with low PNI values (median: 20.03, 95% CI: 11.06–29.03) (p = 0.092). The PNI is a good predictor of OS and CSS in patients with mCSPC. The prediction of PFS, albeit showing a trend towards significance, was not statistically significant, probably due to the small number of cases.

Background: In this paper, it was aimed to evaluate the biomarker potential as well as the effect of the prognostic nutritional index (PNI), which is calculated using the albumin level reflecting nutritional status and lymphocyte count reflecting immune status, in determining the prognosis of metastatic castration-sensitive prostate cancer (mCSPC). Methods: This retrospective observational study included the complete data of 108 patients with mCPSC who were treated for at least three months between January 1, 2010, and June 1, 2021. The relationship between cancer specific survival (CSS), overall survival (OS), progression free survival (PFS) and PNI was evaluated. Kaplan-Meier method for OS, PFS, and CSS, as well as univariate and multivariate Cox regression models were used in statistical analyses. Results: The median age of 108 patients included in the study was 68.54 (61.05-74.19) years. While 71.3% (n = 77) of the patient population were high-volume according to CHAARTED, 52.8% (n = 57) were high-risk based on LATITUDE. 49.75 was determined as the best cut-off point for the PNI. OS (months) was found to be significantly lower in patients with low PNI (median: 34.93, 95% CI: 21.52–48.34) compared to patients with high PNI (median: 65.60, 95% CI: 39.36–91.83) (p=0.016). Patients with high PNI (median: 48.20, 95% CI: 34.66–61.73) had significantly better CSS (months) than patients with low PNI (median: 27.86, 95% CI: 24.16–31.57) (p=0.001). Conclusions: PNI calculated at the time of diagnosis strongly predicts OS and CSS but not PFS in patients with mCSPC.

Renal cell carcinoma (RCC) can cause various paraneoplastic syndromes, including metabolic and hematologic disturbances. Paraneoplastic hypereosinophilia has been reported in a variety of hematologic and solid tumors. Hypereosinophilia due to RCC is very rare and is only available as case reports in the literature. A 66-year-old male patient's thoracoabdominal computed tomography (CT) performed showed an increase in size in the right kidney and a heterogeneous contrasting solid mass of approximately 12 cm x 9 cm, which formed lobulations in its contours. The patient was diagnosed with clear-cell renal carcinoma as a result of a kidney biopsy. In the patient with stage cT4NxM0, the leukocyte count was 40.000/& mu;l and the eosinophil count was 20% in biochemical tests. With these results, the patient was evaluated as having severe paraneoplastic hypereosinophilia due to RCC. The patient was started on sunitinib 50 mg for two weeks on/one week off. No symptoms were observed due to hypereosinophilia. In the evaluation made two weeks after the start of the treatment, it was observed that eosinophil levels decreased to normal rates. Paraneoplastic hypereosinophilia due to renal cell carcinoma may indicate poor prognosis and rapid disease progression. Myelosuppressive therapy is required for symptomatic patients.

Objective: Prostate cancer is the the second common cancer in men in Turkey. We aimed to share our single center experience on the characteristics of patients with metastatic castration sensitive prostate cancer (mCSPC) and the factors affecting survival. Materials and Methods: Between January 2007 and December 2020, 280 patients (aged 18 years and older men) who applied with the diagnosis of metastatic prostate carcinoma were screened in this retrospective cross-sectional study. Sociodemographic and clinicopathological characteristics of the patients were obtained retrospectively from the hospital database. The study variables of the research were included descriptive characteristics of the patients, metastasis sites, treatments, comorbidities of the patients and overal survival were evaluated. For the statistical analysis, descriptive statistics, Chi-Square Test, Fisher Exact Test, Kaplan Meier and Cox Regression model were used as appropriate. Results: A total of 201 patient who applied with the diagnosis of mCSPC were included in this study. The median age of the patients at the time of diagnosis was 68.67 years (43,97-90,48), 43.56% (n=88) of the patients were ≥ 70 years old and 56.43% (n=114) were under 70 years of age. The median follow-up time was 55.5 months, and the median overall survival was found to be 34.93 months (27.90-41.96). 34.7% of the patients were still alive at the time of date cut-off. The median overall survival of the patients was found to be significantly lower in individuals ≥70 years old than under 70 years of age (p=0.032). According to the LATITUDE study the median overall survival of the high-risk group (26.56 months) was statistically significantly lower than in the low-risk group (44.83 months). When the patients were evaluated in terms of disease volume according to CHAARTED, it was found that the median overall survival of the patient group with high-volume disease (29.03 months) was statistically significantly lower than the group with low-volume disease (46.80 months) (p=0.001). Conclusion: In this study, it was shown that being over 70 years old, a low BMI, high volume disease defined as in the CHAARTED trial, and high risk disease defined as in the LATITUDE trial had a negative impact on survival of patients with mCSPC.

Background and Aims: Hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) remain significant global public health issues despite advances in their diagnosis and treatment. Our country is in a medium endemic region for HBV. Reactivation can occur during or after immunosuppressive therapy. Therefore, screening patients before treatment is crucial to prevent reactivation. However, pretreatment screening is often insufficiently emphasized in studies. This study aimed to assess the incidence of HBV and pretreatment screening rates in patients with solid organ tumors at our center. Methods: We included patients aged over 18 years who were treated for solid organ tumors at our center between January 2016 and January 2022. Data on age, sex, histopathological diagnosis, and serological parameters were retrospectively collected. Appropriate HBV screening was defined as the assessment of HBsAg, anti-HBs, and anti-HBc IgG levels prior to the initiation of immunosuppressive therapy. Results: In our study, HBsAg testing was requested for 13.3% of the patients, and anti-HCV testing was requested for 13.3%. Among the patients screened for HBV and HCV, the prevalence rates of HBV and HCV infection were 3.3% and 1%, respectively. Conclusions: Our findings reveal inadequate screening rates for HBV and HCV among patients receiving immunosuppressive therapy. Increasing awareness about screening and implementing regular educational programs are crucial to protect patients from reactivation.